BCK Capital Management LP bought a new stake in shares of STAAR Surgical Company (NASDAQ: STAA) during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund bought 51,006 shares of the medical instruments supplier's stock, valued at approximately $1,371,000. STAAR Surgical accounts

STAAR Surgical jumps 8% after the FDA expands the EVO ICL age range to 21-60, backed by strong safety data and rising demand for LASIK alternatives.

LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded age indication for EVO/EVO+ Visian® Implantable Collamer Lenses, extending use to patients 21 to 60 years old. The approval came shortly after publication of three-year FDA clinical trial safety data, reinforcing.

Credit Industriel ET Commercial bought a new position in shares of STAAR Surgical Company (NASDAQ: STAA) in the third quarter, according to the company in its most recent filing with the SEC. The firm bought 121,258 shares of the medical instruments supplier's stock, valued at approximately $3,258,000. Credit Industriel ET Commercial owned approximately

ABC Arbitrage SA acquired a new position in STAAR Surgical Company (NASDAQ: STAA) in the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund acquired 246,829 shares of the medical instruments supplier's stock, valued at approximately $6,632,000. ABC Arbitrage SA owned 0.50% of

Versor Investments LP purchased a new stake in shares of STAAR Surgical Company (NASDAQ: STAA) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 212,421 shares of the medical instruments supplier's stock, valued at approximately $5,708,000. STAAR Surgical makes up about 1.1% of

Staar Surgical (STAA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (“STAAR” or the “Company”) (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that its Board of Directors (the “Board”) has appointed Warren Foust, President and Chief Operating Officer, and Deborah Andrews, Chief Financial Officer, as interim co-Chief Executive Officers, effective February 1, 2026. Mr. Foust and Ms. Andrews will work t.

Pro-Dex (NASDAQ: PDEX - Get Free Report) and STAAR Surgical (NASDAQ: STAA - Get Free Report) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, institutional ownership, analyst recommendations, earnings, profitability, valuation and dividends. Profitability This table compares Pro-Dex and STAAR Surgical's

STAAR Surgical (NASDAQ: STAA - Get Free Report) and Lancer Orthodontics (OTCMKTS:LANZ - Get Free Report) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, earnings, analyst recommendations, valuation, profitability and risk. Analyst Ratings This is a summary of recent